World Health Organization. Global health risks: Mortality and burden of disease attributable to selected major risks. Geneva: WHO, 2009.
2.
Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG) and ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019; 290: 140-205.
3.
FerenceBAGinsbergHNGrahamI, et al.
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J2017;
38: 2459–2472.
4.
SabatineMSGiuglianoRPKeechAC, et al.
Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med2017;
376: 1713–1722.
5.
BrenerSJTarantiniGLeonMB, et al.
Cardiovascular and noncardiovascular death after percutaneous coronary intervention: Insights from 32 882 patients enrolled in 21 randomized trials. Circ Cardiovasc Interv2018;
11: e006488.
6.
HarrisDELaceyAAkbariA, et al.
Achievement of European guideline-recommended lipid levels post percutaneous coronary intervention: A population-level observational cohort study. Eur J Prev Cardiol. Epub ahead of print 31 March 2020. DOI: 10.1177/2047487320914115.
7.
GittAKLautschDFerrieresJ, et al.
Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II. Atherosclerosis2017;
266: 158–166.
8.
De BackerGJankowskiPKotsevaK, et al.
Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis2019;
285: 135–146.
9.
ZafrirBSalibaWJaffeR, et al.
Attainment of lipid goals and long-term mortality after coronary-artery bypass surgery. Eur J Prev Cardiol2019;
26: 401–408.
10.
WangYYanBPTomlinsonB, et al.
Is lipid goal one-size-fits-all: A review of evidence for recommended low-density lipoprotein treatment targets in Asian patients. Eur J Prev Cardiol2019;
26: 1496–1506.
11.
NielsenSFNordestgaardBG.Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: A nationwide prospective cohort study. Eur Heart J2016;
37: 908–916.
12.
CohenJDAspryKEBrownAS, et al.
Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: Proceedings from a workshop. J Clin Lipidol2013;
7: 573–609.
13.
ChowCKRedfernJHillisGS, et al.
Effect of lifestyle-focused text messaging on risk factor modification in patients with coronary heart disease: A randomized clinical trial. JAMA2015;
314: 1255–1263.
14.
CannonCPKhanIKlimchakAC, et al.
Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease. JAMA Cardiol2017;
2: 959–966.
15.
RayKKWrightRSKallendD, et al.
Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. New Engl J Med. Epub ahead of print 18 March 2020. DOI: 10.1056/NEJMoa1912387.
16.
RayKKBaysHECatapanoAL, et al.
Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med2019;
380: 1022–1032.
17.
FerenceBAGrahamITokgozogluL, et al.
Reprint of: Impact of lipids on cardiovascular health: JACC Health Promotion Series. J Am Coll Cardiol2018;
72: 2980–2995.
